CO6491105A2 - Anticuerpos monoclonales anti cea, humanizados y de afinidad madurada - Google Patents

Anticuerpos monoclonales anti cea, humanizados y de afinidad madurada

Info

Publication number
CO6491105A2
CO6491105A2 CO12014021A CO12014021A CO6491105A2 CO 6491105 A2 CO6491105 A2 CO 6491105A2 CO 12014021 A CO12014021 A CO 12014021A CO 12014021 A CO12014021 A CO 12014021A CO 6491105 A2 CO6491105 A2 CO 6491105A2
Authority
CO
Colombia
Prior art keywords
abms
relates
present
monoclonal antibodies
humanized
Prior art date
Application number
CO12014021A
Other languages
English (en)
Inventor
Thomas U Hofer
Ralf Hosse
Ekkehard Moessner
Pablo Umana
Original Assignee
Roche Glycart Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42985489&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CO6491105(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Roche Glycart Ag filed Critical Roche Glycart Ag
Publication of CO6491105A2 publication Critical patent/CO6491105A2/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3007—Carcino-embryonic Antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Oncology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente invención se refiere a moléculas de unión a antígeno (ABMs). En realizaciones particulares, la presente invención se refiere a anticuerpos monoclonales recombinantes, incluyendo anticuerpos quiméricos, primatizados o humanizados o variantes de los mismos específicos para CEA humano de superficie celular o unido a membrana. Además, la presente invención se refiere a moléculas de ácidos nucleicos codificantes de dichas ABMs, y a vectores y células huésped que comprenden dichas moléculas de ácidos nucleicos. La invención se refiere además a métodos para producir las ABMs de la invención, ya métodos de utilización de dichas ABMs en el tratamiento de enfermedades. Además la presente invención se refiere a ABMs con glucosilación modificada que presentan propiedades terapéuticas mejoradas, incluyendo anticuerpos con unión a receptor de Fc incrementada y función efectora incrementada.
CO12014021A 2009-08-31 2012-01-30 Anticuerpos monoclonales anti cea, humanizados y de afinidad madurada CO6491105A2 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US23850509P 2009-08-31 2009-08-31

Publications (1)

Publication Number Publication Date
CO6491105A2 true CO6491105A2 (es) 2012-07-31

Family

ID=42985489

Family Applications (1)

Application Number Title Priority Date Filing Date
CO12014021A CO6491105A2 (es) 2009-08-31 2012-01-30 Anticuerpos monoclonales anti cea, humanizados y de afinidad madurada

Country Status (23)

Country Link
US (2) US9068008B2 (es)
EP (1) EP2473532B1 (es)
JP (1) JP5744872B2 (es)
KR (1) KR101528013B1 (es)
CN (1) CN102741293B (es)
AR (1) AR078111A1 (es)
AU (1) AU2010288469A1 (es)
BR (1) BR112012003983A2 (es)
CA (1) CA2770174A1 (es)
CL (1) CL2012000551A1 (es)
CO (1) CO6491105A2 (es)
CR (1) CR20120087A (es)
EC (1) ECSP12011698A (es)
HK (1) HK1176951A1 (es)
IL (1) IL218038A0 (es)
MA (1) MA33536B1 (es)
MX (1) MX339608B (es)
PE (1) PE20121552A1 (es)
RU (1) RU2570554C2 (es)
SG (1) SG178567A1 (es)
TW (1) TW201121994A (es)
WO (1) WO2011023787A1 (es)
ZA (1) ZA201200954B (es)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5992710A (ja) * 1982-11-16 1984-05-29 関西電力株式会社 直接水冷線路の立坑部の布設方法
NZ592087A (en) 2001-08-03 2012-11-30 Roche Glycart Ag Antibody glycosylation variants having increased antibody-dependent cellular cytotoxicity
MY190604A (en) 2011-02-10 2022-04-27 Roche Glycart Ag Mutant interleukin-2 polypeptides
CN103476433A (zh) 2011-02-10 2013-12-25 罗切格利卡特公司 改良的免疫疗法
LT2681244T (lt) 2011-03-02 2018-02-12 Roche Glycart Ag Cea antikūnai
EA201892619A1 (ru) 2011-04-29 2019-04-30 Роше Гликарт Аг Иммуноконъюгаты, содержащие мутантные полипептиды интерлейкина-2
EP2748202B1 (en) 2011-08-23 2018-07-04 Roche Glycart AG Bispecific antigen binding molecules
PE20141521A1 (es) 2011-08-23 2014-10-25 Roche Glycart Ag Moleculas biespecificas de union a antigeno activadoras de celulas t
EP2747781B1 (en) 2011-08-23 2017-11-15 Roche Glycart AG Bispecific antibodies specific for t-cell activating antigens and a tumor antigen and methods of use
WO2013054320A1 (en) 2011-10-11 2013-04-18 Tel Hashomer Medical Research Infrastructure And Services Ltd. Antibodies to carcinoembryonic antigen-related cell adhesion molecule (ceacam)
GB201213858D0 (en) 2012-08-03 2012-09-19 Mab Design Ltd Method
ES2848732T3 (es) 2012-08-07 2021-08-11 Roche Glycart Ag Inmunoterapia mejorada
WO2014056783A1 (en) 2012-10-08 2014-04-17 Roche Glycart Ag Fc-free antibodies comprising two fab-fragments and methods of use
ES2775207T3 (es) 2013-02-26 2020-07-24 Roche Glycart Ag Moléculas de unión a antígeno activadoras de linfocitos T biespecíficas específicas para CD3 y CEA
JP6499087B2 (ja) 2013-02-26 2019-04-10 ロシュ グリクアート アーゲー 二重特異性ｔ細胞活性化抗原結合分子
WO2014131711A1 (en) 2013-02-26 2014-09-04 Roche Glycart Ag Bispecific t cell activating antigen binding molecules
US11427647B2 (en) 2014-04-27 2022-08-30 Famewave Ltd. Polynucleotides encoding humanized antibodies against CEACAM1
EP3766902A1 (en) 2014-04-27 2021-01-20 FameWave Ltd. Humanized antibodies against ceacam1
PL3177643T3 (pl) 2014-08-04 2019-09-30 F.Hoffmann-La Roche Ag Dwuswoiste cząsteczki wiążące antygen aktywujące komórki T
DK3789402T3 (da) 2014-11-20 2022-09-19 Hoffmann La Roche Kombinationsbehandling med T-celleaktiverende bispecifikke antigenbindende molekyler og PD-1-aksebindende antagonister
RS60615B1 (sr) 2014-11-20 2020-08-31 Hoffmann La Roche Zajednički laki lanci i postupci upotrebe
AR106188A1 (es) 2015-10-01 2017-12-20 Hoffmann La Roche Anticuerpos anti-cd19 humano humanizados y métodos de utilización
EP3356410B1 (en) 2015-10-02 2021-10-20 F. Hoffmann-La Roche AG Bispecific anti-ceaxcd3 t cell activating antigen binding molecules
AU2016368469B2 (en) 2015-12-09 2023-11-02 F. Hoffmann-La Roche Ag Type II anti-CD20 antibody for reducing formation of anti-drug antibodies
AR107303A1 (es) 2016-01-08 2018-04-18 Hoffmann La Roche Métodos de tratamiento de cánceres positivos para ace utilizando antagonistas de unión a eje pd-1 y anticuerpos biespecíficos anti-ace / anti-cd3, uso, composición, kit
SI3433280T1 (sl) 2016-03-22 2023-07-31 F. Hoffmann-La Roche Ag S proteazo aktivirane bispecifične molekule celic T
CN107663240B (zh) * 2016-07-29 2021-01-12 中国人民解放军第四军医大学 高度糖基化cea特异性结合的单链抗体及其在检测和治疗上的应用
WO2018060301A1 (en) 2016-09-30 2018-04-05 F. Hoffmann-La Roche Ag Bispecific antibodies against cd3
AR115360A1 (es) 2018-02-08 2021-01-13 Genentech Inc Moléculas de unión al antígeno y métodos de uso
TWI849895B (zh) 2018-02-09 2024-07-21 日商小野藥品工業股份有限公司 雙特異性抗體
WO2020259550A1 (zh) * 2019-06-26 2020-12-30 江苏恒瑞医药股份有限公司 抗cea抗体及其应用
EP3990477A1 (en) 2019-06-26 2022-05-04 F. Hoffmann-La Roche AG Fusion of an antibody binding cea and 4-1bbl
CN110862456B (zh) * 2019-09-23 2021-04-09 华道(上海)生物医药有限公司 一种抗癌胚抗原的抗体及其制备方法和用途
CN110713539B (zh) * 2019-09-23 2021-04-16 华道(上海)生物医药有限公司 一种抗癌胚抗原的抗体及其制备方法和用途
CA3153085A1 (en) 2020-06-19 2021-12-23 F. Hoffmann-La Roche Ag Antibodies binding to cd3 and cd19
EP4100028A4 (en) 2020-08-20 2023-07-26 A2 Biotherapeutics, Inc. COMPOSITIONS AND METHODS FOR THE TREATMENT OF MESOTHELIN-POSITIVE CANCERS
AU2021329375A1 (en) 2020-08-20 2023-04-20 A2 Biotherapeutics, Inc. Compositions and methods for treating ceacam positive cancers
KR20240135660A (ko) * 2022-01-27 2024-09-11 얀센 바이오테크 인코포레이티드 향상된 단백질 조성물
AU2023237620A1 (en) 2022-03-23 2024-08-29 Synaffix B.V. Antibody-conjugates for targeting of tumours expressing carcinoembyronic antigen

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
EP0617706B1 (en) 1991-11-25 2001-10-17 Enzon, Inc. Multivalent antigen-binding proteins
US5872215A (en) 1991-12-02 1999-02-16 Medical Research Council Specific binding members, materials and methods
CA2135059A1 (en) * 1992-05-07 1993-11-11 John L. Toner Complexing agents and targeting immunoreagents
GB9317423D0 (en) * 1993-08-21 1993-10-06 Imp Cancer Res Tech Monoclonal antibodies
GB9324807D0 (en) 1993-12-03 1994-01-19 Cancer Res Campaign Tech Tumour antibody
US6001358A (en) 1995-11-07 1999-12-14 Idec Pharmaceuticals Corporation Humanized antibodies to human gp39, compositions containing thereof
US6417337B1 (en) 1996-10-31 2002-07-09 The Dow Chemical Company High affinity humanized anti-CEA monoclonal antibodies
DK2180007T4 (da) 1998-04-20 2017-11-27 Roche Glycart Ag Glycosyleringsteknik for antistoffer til forbedring af antistofafhængig cellecytotoxicitet
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
EP2275541B1 (en) 1999-04-09 2016-03-23 Kyowa Hakko Kirin Co., Ltd. Method for controlling the activity of immunologically functional molecule
CA2417415C (en) 2000-07-31 2012-10-09 Biolex, Inc. Expression of biologically active polypeptides in duckweed
US6946292B2 (en) 2000-10-06 2005-09-20 Kyowa Hakko Kogyo Co., Ltd. Cells producing antibody compositions with increased antibody dependent cytotoxic activity
US6815175B2 (en) * 2001-03-16 2004-11-09 Cornell Research Foundation, Inc. Anti-amyloid peptide antibody based diagnosis and treatment of a neurological disease or disorder
US7321026B2 (en) 2001-06-27 2008-01-22 Skytech Technology Limited Framework-patched immunoglobulins
NZ592087A (en) 2001-08-03 2012-11-30 Roche Glycart Ag Antibody glycosylation variants having increased antibody-dependent cellular cytotoxicity
AU2002337935B2 (en) 2001-10-25 2008-05-01 Genentech, Inc. Glycoprotein compositions
US20040093621A1 (en) 2001-12-25 2004-05-13 Kyowa Hakko Kogyo Co., Ltd Antibody composition which specifically binds to CD20
US8932825B2 (en) 2001-12-27 2015-01-13 Glycofi Inc. Method to engineer mammalian-type carbohydrate structures
US7432063B2 (en) 2002-02-14 2008-10-07 Kalobios Pharmaceuticals, Inc. Methods for affinity maturation
US20040132101A1 (en) 2002-09-27 2004-07-08 Xencor Optimized Fc variants and methods for their generation
US20070148171A1 (en) * 2002-09-27 2007-06-28 Xencor, Inc. Optimized anti-CD30 antibodies
EP2319935B1 (en) 2002-03-19 2016-04-27 Stichting Dienst Landbouwkundig Onderzoek GnTIII (UDP-N-acetylglucosamine:Beta -D mannoside Beta (1,4)-N-acetylglucosaminyltransferase III) expression in plants.
EP1498491A4 (en) 2002-04-09 2006-12-13 Kyowa Hakko Kogyo Kk METHOD FOR INCREASING THE ACTIVITY OF AN ANTIBODY COMPOSITION FOR BINDING TO THE FC GAMMA RECEPTOR IIIA
EP1498490A4 (en) 2002-04-09 2006-11-29 Kyowa Hakko Kogyo Kk PROCESS FOR PREPARING ANTIBODY COMPOSITION
ES2362419T3 (es) 2002-04-09 2011-07-05 Kyowa Hakko Kirin Co., Ltd. Células con depresión o deleción de la actividad de la proteína que participa en el transporte de gdp-fucosa.
WO2003085107A1 (fr) 2002-04-09 2003-10-16 Kyowa Hakko Kogyo Co., Ltd. Cellules à génome modifié
JP4832719B2 (ja) 2002-04-09 2011-12-07 協和発酵キリン株式会社 ＦｃγＲＩＩＩａ多型患者に適応する抗体組成物含有医薬
US7232888B2 (en) 2002-07-01 2007-06-19 Massachusetts Institute Of Technology Antibodies against tumor surface antigens
CA2494310A1 (en) * 2002-08-01 2004-02-12 Immunomedics, Inc. Alpha-fetoprotein immu31 antibodies and fusion proteins and methods of use thereof
AU2003270152A1 (en) 2002-09-12 2004-04-30 Greenovation Biotech Gmbh Protein production method
US7781197B2 (en) 2002-12-20 2010-08-24 Greenovation Biotech Gmbh Transformed bryophyte cell having disrupted endogenous alpha 1,3-fucosyl and beta 1,2-xylosyl transferase encoding nucleotide sequences for the production of heterologous glycosylated proteins
EP2368578A1 (en) 2003-01-09 2011-09-28 Macrogenics, Inc. Identification and engineering of antibodies with variant Fc regions and methods of using same
KR101292000B1 (ko) 2003-01-22 2013-08-01 로슈 글리카트 아게 융합 구성체와 Ｆｃ 수용체 결합 친화도 및 이펙터 기능이증가된 항체를 생성하기 위한 이의 용도
WO2004101790A1 (en) * 2003-05-14 2004-11-25 Domantis Limited A process for recovering polypeptides that unfold reversibly from a polypeptide repertoire
LT2681244T (lt) * 2011-03-02 2018-02-12 Roche Glycart Ag Cea antikūnai

Also Published As

Publication number Publication date
HK1176951A1 (en) 2013-08-09
CN102741293B (zh) 2015-04-01
KR101528013B1 (ko) 2015-06-16
CN102741293A (zh) 2012-10-17
CL2012000551A1 (es) 2012-10-12
CA2770174A1 (en) 2011-03-03
ZA201200954B (en) 2014-07-30
BR112012003983A2 (pt) 2021-09-14
SG178567A1 (en) 2012-04-27
US20110104148A1 (en) 2011-05-05
US20160075795A1 (en) 2016-03-17
AR078111A1 (es) 2011-10-12
JP5744872B2 (ja) 2015-07-08
CR20120087A (es) 2012-03-22
US9068008B2 (en) 2015-06-30
JP2013502913A (ja) 2013-01-31
PE20121552A1 (es) 2012-11-26
KR20120060874A (ko) 2012-06-12
RU2570554C2 (ru) 2015-12-10
AU2010288469A1 (en) 2012-03-01
MA33536B1 (fr) 2012-08-01
MX2012002461A (es) 2012-03-14
IL218038A0 (en) 2012-04-30
WO2011023787A1 (en) 2011-03-03
TW201121994A (en) 2011-07-01
RU2012112340A (ru) 2013-10-10
EP2473532A1 (en) 2012-07-11
ECSP12011698A (es) 2012-03-30
EP2473532B1 (en) 2017-06-21
MX339608B (es) 2016-05-31

Similar Documents

Publication Publication Date Title
CO6491105A2 (es) Anticuerpos monoclonales anti cea, humanizados y de afinidad madurada
ECSP21023271A (es) Anticuerpos cd20 con función del efector y afinidad de enlace al receptor fc mejoradas
AR055137A1 (es) Moleculas de union al antigeno modificadas con actividad de senalizacion celular alterada
TW200720439A (en) Antigen binding molecules directed to mcsp and having increased fc receptor binding affinity and effector function
AR052285A1 (es) Moleculas de union al antigeno que fijan egfr, vectores que las codifican y usos de las mismas
WO2008017963A3 (en) Antigen binding molecules that bind egfr, vectors encoding same, and uses thereof
EA030777B9 (ru) Анти-альфа-синуклеинсвязывающие молекулы
MX2010009190A (es) Anticuerpos anti-c5ar humanizados.
BR112012018914A2 (pt) "anticorpo humanizado, proteína de ligação de antígeno, molécula de ácido nucleico, vetor de expressão, célula hospedeira recombinante, proteína de ligação de anticorpo ou de antígeno, métodos para a produção de uma proteína de ligação de antígeno e para tratar um sujeito afetado por uma doença autoimune ou inflamatória, e, composição farmacêutica."
UA114108C2 (uk) Моноклональне антитіло для застосування в діагностиці і терапії злоякісних пухлин і аутоімунного захворювання
CR8389A (es) Anticuerpos cd20 con funcion del efector y afinidad de enlace al receptor fc mejoradas

Legal Events

Date Code Title Description
FC Application refused